MONTE CARLO SIMULATION & PK-PD TARGET ATTAINMENT ANALYSIS:
|
|
- Ursula Ferguson
- 5 years ago
- Views:
Transcription
1 MONTE CARLO SIMULATION & PK-PD TARGET ATTAINMENT ANALYSIS: Application to Estimation of MIC Breakpoints Paul G. Ambrose, Pharm.D. Director, Division of Infectious Diseases, Cognigen Corporation; Adjunct Professor, University of the Pacific, School of Health Sciences
2 OBJECTIVES! To provide a brief history of Monte Carlo Simulation! To review the types of information gained from nonclinical and clinical PK-PD models of infection! To review the role of Monte Carlo Simulation in PK-PD target attainment analysis in establishing in vitro susceptibility breakpoints.
3 MONTE CARLO SIMULATION Early History! Named after city in Monaco where roulette remains a common game of chance " The roulette wheel may be viewed as a simple random number generator!! Early history may predate the 17 th century Buffon's original form was to drop a needle of length L at random of grid of parallel lines of spacing D. Georges Buffon For For L L less less than than or or equal equal D we we obtain obtain P(needle P(needle intersects intersects the the grid) grid) = 2 L L // PI PI D If If we we drop drop the the needle needle N times times and and count count R intersections intersections we we obtain obtain P P = R // N, N, PI PI = 2 L L N // R D. D.
4 MONTE CARLO SIMULATION Development as a Research Tool! The name Monte Carlo Simulation and modern development dates from World War II! Work involved the direct simulation of the probabilistic problems associated with random neutron diffusion in fissile material John von Neumann
5 MONTE CARLO SIMULATION Application to Antiinfective Drug Development! Introduced to our community of practice by Drusano (presented to CDER, FDA in 1998) 2 George Drusano! Currently being utilized for: " Identification of dose and interval during drug development " In evaluations of the adequacy of drug regimens " Estimating susceptibility breakpoints " Pharmacoeconomic studies
6 THINGS YA REALLY WANT TO KNOW Requirements for Rational Drug Evaluation #Identify pharmacodynamic goal of therapy Can come from non-clinical models of infection or clinical data $Protein binding data don t ignore! %Organism MIC probability mass function(s) can come from local, regional, national or international data &Pharmacokinetic variability can come from Phase-I or Phase-II III population analyses and may focus on special patient populations of interest GL Drusano
7 PK-PD GOAL OF THERAPY In Vitro Models of Infection Hollow-Fiber Cartridge Cross-Section Lumen of hollow fiber Hollow-Fiber PK-PD Model HFC Drug Wall of hollow fiber Bacteria Peripheral compartment Diluent Reservoir Central Reservoir Elimination Reservoir
8 IN VITRO MODEL DATA AUC 24 :MIC & Response: S. pneumoniae Logarithmic phase cultures (5x10 7 CFU/mL) of S. pneumoniae introduced into peripheral compartment Peak:MIC 2.5; elimination half-life altered to provide AUC:MIC ratios of Samples removed from peripheral compartment at 0,2,4,8,12,24,30 hrs Viable bacterial counts measured by plating serial 10-fold dilutions of each sample into Todd-Hewitt agar & incubating overnight at 37 C in 5%CO 2 Lowest dilution plated was 0.1mL. Lister PD. Pharmacodynamics of Gatifloxacin Against Streptococcus pneumoniae in an in vitro Pharmacokinetic Model: Impact of AUC:MIC Ratios on Eradication. Antimicob Agents and Chemother 2002:46:69-74.
9 PK-PD GOAL OF THERAPY Animal Models of Infection -2 Hr 0 Hr Infect Begin Therapy 24 Hr 96 Hr Sacrifice, Harvest, Homogenize Muscle
10 ANIMAL DATA AUC:MIC & Response: S. pneumoniae Survival (Percent) R 2 =82% AUC 24 /MIC (Free Drug) Log 10 CFU/Thigh over 24 Hrs R 2 =76% AUC 24 /MIC (Free Drug) ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and sitafloxacin Craig WA, Andes DR. Correlation of the Magnitude of the AUC 24 /MIC for 6 Fluoroquinolones against Streptococcus pneumoniae with Survival and Bactericidal Activity in an Animal Model. In Abstracts of the 40th ICAAC, Toronto, Canada, Sept , Abs-289;
11 PK-PD GOAL OF THERAPY Clinical Data! Clinical validation of PK-PD targets has been slow " Too few target patient population trials collect pharmacokinetic data " Too narrow range of exposures studied (usually one fixed dosing regimen) " Phase-III trials designed to maximize response- few failuresthus, difficult to model exposure-response relationships! However, there are examples " Ciprofloxacin " Levofloxacin X 2 " Grepafloxacin " Gatifloxacin " Everninomicin " Linezolid
12 PK-PD GOAL OF THERAPY Clinical Data: Quinolones & S. pneumoniae! Data from 2 Phase-III, double-blind, randomized, multicenter trials.! Patients received either levofloxacin 500-mg Q24h or gatifloxacin 400-mg Q24h " 778 adult patients with either community-acquired pneumonia or acute exacerbation of chronic bronchitis. " 635 patients were clinically evaluable. " 376 patients were both clinically and microbiologically evaluable. " 58 patients had CAP or ABECB associated with Streptococcus pneumoniae. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infection. Antimicrob Agents Chemother 2001;45:
13 CART DETERMINED BREAKPOINT Microbiological Response: Quinolones & S. pneumoniae Patients Patients fu AUC:MIC <33.7 fu AUC:MIC fu AUC:MIC < Patients; Patients; 5 Success, Success, 1 Failure Failure fu AUC:MIC Patients; Patients; 2 Success, Success, 3 Failure Failure Patients; Patients; Success, Success, 0 Failure Failure Implemented in S-Plus 2000 professional series release Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infection. Antimicrob Agents Chemother 2001;45:
14 CLINICAL DATA AUC 24 :MIC & Response: Quinolones & S. pneumoniae Model fit to assess probability of bacterial eradication:log likelihood chi square 6.379; p= Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infection. Antimicrob Agents Chemother 2001;45:
15 THINGS YA REALLY WANT TO KNOW Requirements for Rational Drug Evaluation #Identify pharmacodynamic goal of therapy can come from non-clinical models of infection or clinical data $Protein binding data don t ignore! %Organism MIC probability mass function(s) can come from local, regional, national or international data &Pharmacokinetic variability can come from Phase-I or Phase-II III population analyses and may focus on special patient populations of interest GL Drusano
16 PROTEIN BINDING Critical Component to Describing Anti-Infective PK-PD Drug bound to proteins can neither distribute to the site of effect, nor is available to bind to bacterial receptor sites In the simplest cases: total drug ' fu In more complex cases: effect of protein binding depends upon the extent of plasma protein binding and the relative affinity to plasma protein and bacterial receptor sites Simple corrections made for protein binding more likely will closely describe the true PK-PD relationship than not considering it at all PK-PD Working Group. Towards a Consensus and Working Guidelines in Antimicrobial Pharmacodynamics. In Abstracts of the 42nd ICAAC, San Diego, CA, Sept , Abs-164
17 PROTEIN BINDING Free- vs. Total-Drug & Animal Survival Free-Drug Total-Drug AUC 24 :MIC Gati Gemi Levo Moxi Gare Craig WA, Andes DR. In Abstracts of the 40th ICAAC, Toronto, Canada, Sept , Abs-289; Nicolau DP, et al. In Abstracts of the 40th ICAAC, Toronto, Canada, Sept , Abs-290.
18 THINGS YA REALLY WANT TO KNOW Requirements for Rational Drug Evaluation #Identify pharmacodynamic goal of therapy can come from non-clinical models of infection or clinical data $Protein binding data don t ignore! %Organism MIC probability mass function(s) can come from local, regional, national or international data &Pharmacokinetic variability can come from Phase-I or Phase-II III population analyses and may focus on special patient populations of interest GL Drusano
19 QUINOLONES & S. pneumoniae Single-Point PK-PD Analysis 150 Gati better Levo better yet 136 Trova great AUC 24 :MIC Cipro bad Levo good Cipro 750mg BID Levo 500mg QD Gati 400mg QD Levo 750mg QD Trova 200mg QD STANDARD DAILY DOSE
20 PROBABILITY DISTRIBUTIONS Gatifloxacin & S. pneumoniae.095 Gatifloxacin AUC 24 Distribution 0.8 Gatifloxacin S. pneumoniae MIC Distribution 0.7 N = 6,700 Probability mg Q24 hr, steady state AUC 24 (mcg h/ml) MIC (mcg/ml) Ambrose PG, Grasela DM. The Use of Monte Carlo Simulation to Examine the Pharmacodynamic Variance of Drugs: Fluoroquinolone Pharmacodynamics Against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease 2000;38:
21 LIMITATIONS Single-point PK-PD Analysis Variability in the pharmacokinetic and microbiological data are not taken into consideration. The metrics developed apply to a limited number of clinical instances. Provide information on what is possible, not on what is probable. Ambrose PG, Quintiliani R. Limitations of Single-Point Pharmacodynamic Analysis. Pediatric Infectious Disease Journal 2000;19:769.
22 PK-PD ANALYSIS An Ideal one should... Take into account all possible drug exposures and their probabilities following standard dosing Include all pathogen MIC values treated clinically This will provide more complete information regarding the likelihood an agent will effectively treat a patient infected with a particular organism.
23 MONTE CARLO SIMULATION Applied to PK-PD Generate Random PK PK and and MIC MIC Values From Data Set Set Calculate PK-PD Exposure Measure Plot Plot Results in in a Probability Chart Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime-time. Current Opinion in Microbiology 2000;3:
24 A CASE STUDY Issue before the NCCLS Initial breakpoints of 0.5-, 1.0-, and 2.0-mcg/mL for both ceftiaxone and cefotaxime against S. pneumoniae Manufacturer of ceftriaxone submits robust data supporting breakpoint change to 1.0-, 2.0-, and 4.0- mcg/ml Significantly less data available for cefotaxime Historically both agents have been treated as therapeutic alternatives Different breakpoints for each agent likely to be problematic for clinical laboratories
25 CEFTRIAXONE Model Assumptions CEFTRIAXONE VOLUME OF DISTRIBUTION Mean 9.0 L SD mg LITERS Time > MIC (hours) = (In Dose/(Vd/fu) - In MIC) (0.693/T 1/2 ) CEFTRIAXONE SERUM T1/2 Mean 6.2 hrs SD TIME-HOURS MIC Relative Probability TSN Database-USA 01/01/ /30/1999; Patel IH, et al. Pharmacokinetics of Ceftriaxone in Humans. Antimicrob Agents Chemother 1991;20: ; Yuk J, et al. Clinical Pharmacokinetics of Ceftriaxone. Clin Pharmacokinet 1989;17:
26 RESULTS-CEFTRIAXONE 1-Gm Q24 hrs. PK-PD Target Attainment Rate PK-PD Target (T>MIC) MIC 30% 40% 50% 60% S? I? R? Entire MIC Dist PCN-S PCN-I PCN-R Dudley MN, Ambrose PG. Monte Carlo Simulation of new cefotaxime, ceftriaxone and cefepime susceptibility breakpoints for S. pneumoniae, including strains with reduced susceptibility to penicillin. In Abstracts of the 42nd ICAAC, San Diego, CA, Sept , Abs-635
27 RESULTS-CEFOTAXIME 1-Gm Q8 hrs. PK-PD Target Attainment Rate PK-PD TARGET (T>MIC) MIC 30% 40% 50% 60% S? I? R? Entire MIC Dist PCN-S PCN-I PCN-R Dudley MN, Ambrose PG. Monte Carlo Simulation of new cefotaxime, ceftriaxone and cefepime susceptibility breakpoints for S. pneumoniae, including strains with reduced susceptibility to penicillin. In Abstracts of the 42nd ICAAC, San Diego, CA, Sept , Abs-635
28 RESULTS-CEFOTAXIME 1-Gm Q12 hrs. PK-PD Target Attainment Rate PK-PD TARGET (T>MIC) MIC 30% 40% 50% 60% S? I? R? Entire MIC Dist PCN-S PCN-I PCN-R Dudley MN, Ambrose PG. Monte Carlo Simulation of new cefotaxime, ceftriaxone and cefepime susceptibility breakpoints for S. pneumoniae, including strains with reduced susceptibility to penicillin. In Abstracts of the 42nd ICAAC, San Diego, CA, Sept , Abs-635
29 PK-PD and Monte Carlo Simulation Powerful Tool with Drug Development, Regulatory and Clinical Application Pharmacokinetics PK Parameter!Animal!Phase-I!Phase-II!Patient Population Microbiology MIC!Local Surveillance!National Surveillance Mathematical Model Pharmacodynamics Change in Log CFU/Thigh 0 vs. 24h Cp t = A ' e -αt 1 - e -ατ + B ' e-βt + C ' e-δt 1 - e -βτ 1 - e -δτ ' fu !In vitro Free Drug AUC:MIC models!animal models!human data
30 THANK YOU FOR YOUR ATTENTION
31 MONTE CARLO SIMULATION RESULTS Ceftazidime PK-PD Target Attainment Rate CEFTAZIDIME Every 6 Hrs Every 8 Hrs Every 12 Hrs % T>MIC hrs >MIC g MIC: g MIC: Recommend: S I R Rationale/comments: Most frequent clinical use Q 8 h dosing 2 g dose covers intermediate range Paul G. Ambrose/Mike N. Dudley
32 MONTE CARLO SIMULATION RESULTS Cefepime PK-PD Target Attainment Rate CEFEPIME Every 8 Hrs Every 12 Hrs % T>MIC hrs >MIC g MIC: g MIC: Recommend: S I R Rationale/comments: Most frequent clinical use Q 12 h dosing 2 g dose covers intermediate range Paul G. Ambrose/Mike N. Dudley
33 MONTE CARLO SIMULATION RESULTS Ceftriaxone PK-PD Target Attainment Rate CEFTRIAXONE Every 12 Hrs Every 24 Hrs % T>MIC hrs >MIC g MIC: g MIC: Recommend: S I R Rationale/comments: Most frequent clinical use1 g Q 24 h dosing 2 g dose covers intermediate range Paul G. Ambrose/Mike N. Dudley
34 MONTE CARLO SIMULATION RESULTS Cefotaxime PK-PD Target Attainment Rate CEFOTAXIME Every 6 Hrs Every 8 Hrs Every 12 Hrs % T>MIC hrs >MIC g MIC: g MIC: Recommend: S I R Rationale/comments: Most frequent clinical use 1 g Q 8 h dosing 2 g dose covers intermediate range Paul G. Ambrose/Mike N. Dudley
35 MONTE CARLO SIMULATION Structural Model or Population Model? Depends upon the agent s place in development Depends upon the question being asked of the data Time > MIC (hours) = (In Dose/(Vd/fu) - In MIC) (k e ) Mean Vector Parameters Cl Vc Ka Cp t = A ' e -αt 1 - e -ατ + B ' e-βt + C ' e-δt 1 - e -βτ 1 - e -δτ ' fu 9.36E E E+01 Variance-Covariance Matrix Cl Vc Ka Cl 2.23E-02 fu AUC 24 :MIC = fu ' AUC 24 MIC Vc Ka -6.22E E E E E-01
36 PROTEIN BINDING Free- vs. Total-Drug & Animal Survival Drug MIC % Peak T 1/2 (mg/l) bound (mg/l) (hr) 50 (1) CD 50 (mg/kg) (2) (3) (4) (5) (6) (7) % free antibiotic Merrikin DJ, Briant J, Rolinson GN. Effect of Protein Binding in Antibiotic Activity in vivo. J Antimicrob Chemother 1983;11:
37 Animal Models of Infection T>MIC & Response to Therapy: S. pneumoniae Mice rendered neutropenic & infection induced by IM injection of 0.1mL of 10 5 to 10 6 CFU S. pneumoniae Animals received 7 mg/kg alone or in combination with clavulanate (ratio 4:1) every 8 hrs. Each data point represents the mean of two thighs. Andes D, Craig WA. In vitro activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determination. Antimicrob Agents Chemother 1998;42:
38 CEFOTAXIME Model Assumptions One compartment model: is Time > MIC (hours) = (In Dose/(Vd/fu) - In MIC) (0.693/T 1/2 ) where Vd is the volume of distribution, T 1/2 is the serum elimination half-life, and fu the fraction of unbound drug Log-normal distribution for pk parameters: T 1/2 : hours Vd: L/kg Protein-binding 31 to 41% MIC PDF from 1998 SENTRY data (n=5928) 1-Gram intravenous dose of cefotaxime Q8 & Q12 hours
Pharmacodynamics: the methods
Pharmacodynamics: the methods In vitro models Animal models Clinical studies Population studies With the support of Wallonie-Bruxelles-International 3B-1 Pharmacodynamics: the methods "un peu de tout "
More informationSCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past
Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated
More informationBasic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics
Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics This patient needs antibiotics. But which ones? Intensive care patient Ceftazidime,
More informationPharmacodynamic indices in targeting therapy of critical infections
Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationEstimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus
Estimation of In Vitro Susceptibility Breakpoints for Tigecycline Against Staphylococcus aureus Alison K Meagher, PharmD Cognigen Corporation 45 th ICAAC December 17, 2005 Julie Passarell, M.A. Cognigen
More information%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.
THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 159( 55 ) ( 2 15 ) %T MIC MIC 2002 30%T MIC 50%T MIC 1000 mg 3 3 /day Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationMRSA Micro Scan Pos Combo 6J DADE BEHRING VCM
PKPD MRSA 1 1 2 1 1 2 17 1 26 17 3 16 vancomycinvcm methicillin-resistant Staphylococcus aureusmrsa 31 pharmacokineticpkparameter retrospective VCM 21 10 PK parameter Mann- Whitney U-test Cmax 37.1 µ gml29.942
More informationESCMID Online Lecture Library. by author
Disclosures Pk/Pd of antifungal drugs Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker Dosing should be such that the level of antmicrobial
More informationDisclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past
Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.
More informationTowards clinical Applications of PK-PD in specific situations
Towards clinical Applications of PK-PD in specific situations P.M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy, Catholic University of Louvain, Brussels, Belgium with many
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationJohan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics
Exposure - Response Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics ACTVITY in vitro (MIC) CONCENTRATIONS in vivo (PK) DOSING regimen Other factors ANTMICROBIAL EFFICACY (Microbiological
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationProfessor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence
Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs
More informationLong Half-life Drugs in Infectious Diseases: Implications and Complications
Long Half-life Drugs in Infectious Diseases: Implications and Complications In Session: Drugs That Just Won t Leave: From Stars of the Party to Unwelcome Guests Annual Meeting of the AAPS, San Diego, California
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationPopulation-based approaches: Regulatory issues and Population simulations
Population-based approaches: Regulatory issues and Population simulations Michael R. Jacobs, MD, PhD Case Western Reserve University University Hospitals of Cleveland Cleveland, OH Topics Regulatory issues
More informationPD Targets for Various Infection Types: Stasis vs. 1-Log Kill vs. 2 Log Kill
PD Targets for Various Infection Types: Stasis vs. 1-Log Kill vs. 2 Log Kill G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation University of Florida To have insight into appropriate
More informationDoripenem: pharmacokinetics and pharmacodynamics. Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD
16/04/2009 1 Doripenem: pharmacokinetics and pharmacodynamics Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD Unité de Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationAntibiotic Usage Related to Microorganisms Pattern and MIC
Antibiotic Usage Related to Microorganisms Pattern and MIC DR. Dr. Latre Buntaran Sp.MK(K) Secretary General PERDALIN Head of Compartment of Infection Control PERSI Doripenem: Potent
More informationEMA Workshop Estimating the Probability of Target Attainment
EMA Workshop Estimating the Probability of Target Attainment G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation University of Florida Attainment We all tend to think problems
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationIs the package insert correct? PK considerations
Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationEfficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae Strains in a rabbit meningitis model.
AAC Accepts, published online ahead of print on 3 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00285-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 1 2 Efficacy
More informationDepartment of Pharmacy Services, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; 2
Pathogens 2015, 4, 599-605; doi:10.3390/pathogens4030599 Article OPEN ACCESS pathogens ISSN 2076-0817 www.mdpi.com/journal/pathogens Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for
More informationHigh-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia
High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia Review Andrew F. Shorr, MD, MPH, FCCP Department of Medicine Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington,
More informationElsje Pienaar 1,2, Jansy Sarathy 3, Brendan Prideaux 3, Jillian Dietzold 4, Véronique Dartois 3, Denise E. Kirschner 2 and Jennifer J.
Supplement to Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach Elsje Pienaar 1,2, Jansy Sarathy 3, Brendan
More informationDrug Management in CRRT
Drug Management in CRRT Jeffrey Lipman, FCICM, MD Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Bruce A. Mueller, PharmD, FCCP, FASN Clinical, Social & Administrative
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationMacrolides & Ketolides. Objectives. Protein Synthesis
Macrolides & Ketolides Elizabeth D. Hermsen, Pharm.D. Infectious Diseases Research Fellow University of Minnesota College of Pharmacy bjectives Participant should be able to explain macrolide/ketolide
More informationManagement of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm
Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm DRUG PROFILE Gary Patou, Glenn Tillotson & Joseph Blondeau Author for correspondence University
More informationThe general Concepts of Pharmacokinetics
The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique
More informationEnhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models
Journal of Antimicrobial Chemotherapy (25) 56, 365 37 doi:.93/jac/dki24 Advance Access publication 7 July 25 Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection
More informationIntegration of Target Site Pharmacokinetics and in-vitro Pharmacodynamics in the Assessment of Existing and New Anti-Infective Agents
Louvain Drug Research Institute Séminaire de pathologie infectieuse Integration of Target Site Pharmacokinetics and in-vitro Pharmacodynamics in the Assessment of Existing and New Anti-Infective Agents
More informationNephrotoxicity. Pros and Cons of the article: Relationship between Initial Vancomycin
Pros and Cons of the article: Relationship between Initial Vancomycin Nephrotoxicity among Hospitalized Patients Diane M. Cappelletty, Pharm.D. Associate Professor Pharmacy Practice The University of Toledo
More informationDesigning Fluoroquinolone Breakpoints for Streptococcus pneumoniae by Using Genetics instead of Pharmacokinetics-Pharmacodynamics
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2004, p. 3630 3635 Vol. 48, No. 9 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.9.3630 3635.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationChallenges in Therapeutic Drug Monitoring:
Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist
More informationEUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator
EUCAST Frequently Asked Questions Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator Erika Matuschek EUCAST Development Laboratory, Växjö Sweden Monday 24
More informationUse of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary Sinusitis
MAJOR ARTICLE Use of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary Sinusitis Paul G. Ambrose, 1,2 Jack B. Anon, 3 Joel S. Owen, 1 Scott Van Wart, 1 Mary
More informationExtrapolation in antibacterial agents
Extrapolation in antibacterial agents Irja Lutsar University of Tartu, Estonia Maria Fernandez Cortizo- Medicines Agency, Spain EMA meeting, 30.09.2015 Glossary PIP: Paediatric Investigation Plan AHOM:
More informationWhat is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden
What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)
More informationBack to the Future: Using Aminoglycosides Again and How to Dose Them Optimally
INVITED ARTICLE ANTIMICROBIAL RESISTANCE George M. Eliopoulos, Section Editor Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally George L. Drusano, Paul G. Ambrose, Sujata M.
More informationPharmacology and Pharmacokinetics of TB Drugs Part I
Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens
More informationASHP Therapeutic Position Statements 623
ASHP Therapeutic Position Statements 623 Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society
More informationABSTRACT BRIEF REPORT. Alan J. Xiao. Luzelena Caro. Myra W. Popejoy. Jennifer A. Huntington. Ravina Kullar
Infect Dis Ther (2017) 6:137 148 DOI 10.1007/s40121-016-0143-9 BRIEF REPORT PK/PD Target Attainment With Ceftolozane/ Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function,
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationTitle. Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): Issue Date Doc URL. Rights.
Title The Administration of Ciprofloxacin During Continuou Author(s)Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, CitationASAIO Journal, 55(3): 243-245 Issue Date 2009-05 Doc URL http://hdl.handle.net/2115/43035
More informationStreptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin
2009 21 1) 1, 2) 1, 2) 1) 1) 2) 1) 1) 1) 1) 1) 1, 2) 1) 2) 20 2 29 21 1 14 Streptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin (STFX), DX619 S. pneumoniae S. pneumoniae 60
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationMedication Dosing in CRRT
Medication Dosing in CRRT Linda Awdishu, PharmD, MAS Associate Clinical Professor of Pharmacy and Medicine Learning Objectives 1. List the pharmacokinetic changes associated with AKI. 2. Determine the
More informationOutline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก
Pharmacokinetic and pharmacodynamic of anti- tuberculosis drugs Outline PK/PD PK/PD first-line drug กก PK/PD กก Concentration vs time in tissue and other body fluids Pharmacologic or toxicologic effect
More informationRisk Factors for and Impact of Ambulatory Urinary Tract infections Caused by High Mic- Fluoroquinolone Susceptible E.
University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 1-1-2013 Risk Factors for and Impact of Ambulatory Urinary Tract infections Caused by High Mic- Fluoroquinolone Susceptible
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationActivities of Ertapenem, a New Long-Acting Carbapenem, against Penicillin-Sensitive or -Resistant Pneumococci in Experimental Meningitis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2003, p. 1943 1947 Vol. 47, No. 6 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.6.1943 1947.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationPharmacokinetic-Pharmacodynamic (PKPD) Modeling Characterizing Resistance for Predictions of Bacterial Kill in vivo
Pharmacokinetic-Pharmacodynamic (PKPD) Modeling Characterizing Resistance for Predictions of Bacterial Kill in vivo Anders Kristoffersson Pascale David- Pierson, Neil John Parrott, Olaf Kuhlmann, Thierry
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationPZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data. Tawanda Gumbo
PZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data Tawanda Gumbo Office of Global Health University of Texas Southwestern Medical Center, Dallas, Texas The team: this work
More informationTherapeutic drug monitoring of β-lactams
CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics
More information/01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2001, p. 3468 3473 Vol. 45, No. 12 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.12.3468 3473.2001 Copyright 2001, American Society for Microbiology. All Rights
More informationMupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010
Mupirocin Rationale for the EUCAST clinical breakpoints, version 1.0 6 th July 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationbreakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):
REVIEW Breakpoints for intravenously used cephalosporins in Enterobacteriaceae EUCAST and CLSI breakpoints G. Kahlmeter Department of Clinical Microbiology, Central Hospital, Växjö, Sweden ABSTRACT It
More informationCefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing Breakpoints
INVITED ARTICLE MEDICAL MICROBIOLOGY L. Barth Reller and Melvin P. Weinstein, Section Editors Cefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing Breakpoints John D. Turnidge
More informationPharmacokinetic study of garenoxacin in severe renal failure patients
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 141 1 Pharmacokinetic study of garenoxacin in severe renal failure patients YUKA YAMAGISHI 1, 2, MAO HAGIHARA 2, YUKIHIRO HAMADA 2, YUKIHIRO KIMURA 3,
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationCellceutix Corporation Beverly, MA USA Abstract 2969; Presentation 0195; Hall J, 4:00pm. April 27, 2015
ECCMID 2015 Copenhagen, Denmark 25 28 April 2015 Cellceutix Corporation Beverly, MA USA www.cellceutix.com A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Doripenem Use in Pediatrics - Learning from Pharmacokinetic Data of Other Carbapenems Patrick Grove, Tsz-Yin So Journal of Pediatric Sciences; How to cite this article: Grove
More informationPharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically ill patients
Veiga and Paiva Critical Care (2018) 22:233 https://doi.org/10.1186/s13054-018-2155-1 REVIEW Pharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically
More informationGarenoxacin Treatment of Experimental Endocarditis Caused by Viridans Group Streptococci
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2006, p. 1263 1267 Vol. 50, No. 4 0066-4804/06/$08.00 0 doi:10.1128/aac.50.4.1263 1267.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationComment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines. Nouvelles molécules
Comment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines Nouvelles molécules L. Dubreuil Maître de conférences en Pharmacologie Professeur
More informationPK/PD degli antibiotici utilizzati nella sepsi
PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill
More informationContinuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationIn vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae
AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment
More informationTerapia delle infezioni da Pseudomonas aeruginosa MDR
Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa
More informationDetermination of MIC & MBC
1 Determination of MIC & MBC Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationMICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
More informationESCMID Online Lecture Library. by author
Novel PK/PD data on the optimisation of colistin and the carbapenems Diamantis Plachouras Athens, Greece Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course, 31
More informationContinuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients
Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationEvaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis
Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis N. Alsaad 1, R. v Altena 2, A.D. Pranger 1, D. van Soolingen 4, W.C.M. de Lange 2, T.S. van der Werf 4, J.G.W. Kosterink 1,
More informationHigh-Dose, Short-Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradigm
MAJOR ARTICLE High-Dose, Short-Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradigm Lala M. Dunbar, 1 Richard G. Wunderink, 2 Michael P. Habib, 3 Leon G. Smith, 4 Alan M. Tennenberg,
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationAnnual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016
Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Sarah Gierhart and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views
More information